Personal information

Other IDs

Scopus Author ID: 57220192133

Activities

Collapse all

Works (4)

EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV Non-small cell lung cancer (NSCLC): A prospective, multicenter, randomized, controlled phase II study

Radiotherapy and Oncology
2023-07 | Journal article
DOI: 10.1016/j.radonc.2023.109681
Contributors: Ping Peng; Juejun Gong; Yujie Zhang; Shuchang Zhou; Yichen Li; Guang Han; Rui Meng; Yongshun Chen; Ming Yang; Qian Shen et al.
Source: check_circle
Crossref

GTF2E2 is a novel biomarker for recurrence after surgery and promotes progression of esophageal squamous cell carcinoma via miR-139-5p/GTF2E2/FUS axis

Oncogene
2022 | Journal article
DOI: 10.1038/s41388-021-02122-8
EID:

2-s2.0-85120624443

Part of ISSN: 14765594 09509232
Contributors: Zhang, Y.; Zhang, Y.; Ai, B.; Gong, J.; Li, Y.; Yu, S.; Cai, X.; Zhang, L.
Source: Self-asserted source
Gong Juejun via Scopus - Elsevier

The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC

Biomedicine and Pharmacotherapy
2022 | Journal article
DOI: 10.1016/j.biopha.2022.113959
EID:

2-s2.0-85141324821

Part of ISSN: 19506007 07533322
Contributors: Li, S.; Zhu, S.; Wei, H.; Zhu, P.; Jiao, Y.; Yi, M.; Gong, J.; Zheng, K.; Zhang, L.
Source: Self-asserted source
Gong Juejun via Scopus - Elsevier

Tyrosine kinase inhibitors as induction therapy in nonsmall-cell lung cancer

Current Opinion in Oncology
2021 | Journal article
DOI: 10.1097/CCO.0000000000000696
EID:

2-s2.0-85097211297

Part of ISSN: 1531703X 10408746
Contributors: Gong, J.; Zhang, L.
Source: Self-asserted source
Gong Juejun via Scopus - Elsevier
How many people are using ORCID?